News | Prostate Cancer | September 14, 2015

New Prostate Imaging Agent Improves Detection of Metastatic Cancer Cells

Study results show cancer detected in half of subjects with new agent, compared to none with conventional imaging

ImaginAb, prostate imaging agent, prostate cancer, World Molecular Imaging Conference, molecular imaging, PET

September 14, 2015 — ImaginAb Inc. has released interim results from a Phase 2 clinical trial of IAB2M, the company's proprietary imaging agent for management of prostate cancer. IAB2M demonstrated superior performance in detecting disease compared with ProstaScint and conventional imaging technologies including computed tomography (CT) scans, magnetic resonance imaging (MRI) scans and bone scans. In addition, the agent accurately detected metastatic disease in normal-sized lymph nodes, overcoming a major limitation of existing technologies and addressing a key clinical need.

The trial data were presented at the World Molecular Imaging Congress 2015 in Honolulu, Hawaii.

"Accurate detection of extra-prostatic disease in high-risk prostate cancer is critical for providing the best possible care to patients undergoing radical prostatectomy," said Robert Reiter, M.D., co-director of the Genitourinary Oncology Program in UCLA's Jonsson Cancer Center. "However, conventional imaging fails to detect metastatic disease in up to 50 percent of high-risk prostate cancer patients. As our data show, ImaginAb's imaging agent provides a whole-body picture of disease activity, with the potential to change patient management and guide the course of care for best possible outcomes."

Results include the first nine of 20 patients in an ongoing, open-label, Phase 2, single-center trial. Patients received IAB2M intravenously prior to a whole-body positron emission tomography (PET) scan. The agent detected disease in lymph nodes of three of six subjects, later confirmed positive for metastasis at surgery. This is in stark contrast to ProstaScint and conventional imaging, which did not detect metastasis in lymph nodes in any of those subjects.

For more information: www.imaginab.com

Related Content

ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
ScImage and Invia Partnership Announced
News | PACS | September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
Theraclion to Launch Metastatic Breast Cancer Trial Combining Echotherapy and Immunotherapy
News | Focused Ultrasound Therapy | September 18, 2017
September 18, 2017 — Theraclion and co-lead investigator David Brenin, M.D., from the University of Virginia School o
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
Overlay Init